Literature DB >> 27214076

Antibiotic prophylaxis in allogeneic stem cell transplantation-what is the correct choice?

R R Jenq1,2, M R M van den Brink1,2,3.   

Abstract

Mesh：

Year:  2016        PMID： 27214076     DOI： 10.1038/bmt.2016.144

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

Review 1.  Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin.

Authors:  Loris R Lopetuso; Valentina Petito; Franco Scaldaferri; Antonio Gasbarrini
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

2.  Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease.

Authors:  Robert R Jenq; Ying Taur; Sean M Devlin; Doris M Ponce; Jenna D Goldberg; Katya F Ahr; Eric R Littmann; Lilan Ling; Asia C Gobourne; Liza C Miller; Melissa D Docampo; Jonathan U Peled; Nicholas Arpaia; Justin R Cross; Tatanisha K Peets; Melissa A Lumish; Yusuke Shono; Jarrod A Dudakov; Hendrik Poeck; Alan M Hanash; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Eric G Pamer; Marcel R M van den Brink
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-11       Impact factor: 5.742

3.  The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.

Authors:  Ying Taur; Robert R Jenq; Miguel-Angel Perales; Eric R Littmann; Sejal Morjaria; Lilan Ling; Daniel No; Asia Gobourne; Agnes Viale; Parastoo B Dahi; Doris M Ponce; Juliet N Barker; Sergio Giralt; Marcel van den Brink; Eric G Pamer
Journal:  Blood       Date:  2014-06-17       Impact factor: 22.113

4.  Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras.

Authors:  J M Jones; R Wilson; P M Bealmear
Journal:  Radiat Res       Date:  1971-03       Impact factor: 2.841

5.  Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial.

Authors:  D W Beelen; A Elmaagacli; K D Müller; H Hirche; U W Schaefer
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

6.  Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Ying Taur; Joao B Xavier; Lauren Lipuma; Carles Ubeda; Jenna Goldberg; Asia Gobourne; Yeon Joo Lee; Krista A Dubin; Nicholas D Socci; Agnes Viale; Miguel-Angel Perales; Robert R Jenq; Marcel R M van den Brink; Eric G Pamer
Journal:  Clin Infect Dis       Date:  2012-06-20       Impact factor: 9.079

7.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

8.  Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment.

Authors:  R Storb; R L Prentice; C D Buckner; R A Clift; F Appelbaum; J Deeg; K Doney; J A Hansen; M Mason; J E Sanders; J Singer; K M Sullivan; R P Witherspoon; E D Thomas
Journal:  N Engl J Med       Date:  1983-02-10       Impact factor: 91.245

Review 9.  Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

10.  Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.